Advances in the use of monoclonal antibodies in cancer radiotherapy

Pharmaceutical Science and Technology Today

Volumn 3, Issue 3, 2000, Pages 90-98

  Govindan, Serengulam V ^a   Goldenberg, David M ^b   Hansen, Hans J ^a   Griffiths, Gary L ^a  

^a IMMUNOMEDICS INC   (United States)

^b GARDEN STATE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASTATINE 211; BISMUTH 212; BISMUTH 213; BISPECIFIC ANTIBODY; CAMPTOTHECIN; COPPER 67; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; IODINE 131; LUTETIUM 177; MONOCLONAL ANTIBODY; RADIOISOTOPE; RHENIUM 188; STREPTAVIDIN; UNCLASSIFIED DRUG; YTTRIUM 90;

BLOOD DISEASE; BREAST CARCINOMA; CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONJUGATION; DRUG TARGETING; HUMAN; MOUSE; NONHUMAN; RADIOIMMUNOTHERAPY; RADIOSENSITIZATION; RAT; REVIEW; SOLID TUMOR;

EID: 0034163955     PISSN: 14615347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1461-5347(00)00241-8     Document Type: Review

References (63)

1. Goldenberg D.M. Cancer Therapy with Radiolabeled Antibodies. 1995;CRC Press Boca Raton, FL, USA.
2. Goldenberg D.M. Monoclonal antibodies in cancer detection and therapy. Am. J. Med. 94:1993;297-312.
3. Rosler H.et al. Endoarterial radionuclide embolizing tumor therapy. Schubiger P.A., Hasler P.H. Radionuclides for Therapy. 1986;227-244 Hoffmann-LaRoche, Basel, Switzerland.
4. Schubiger P.A.et al. Vehicles, chelators, and radionuclides: choosing the 'building blocks' of an effective therapeutic radioimmunoconjugate. Bioconj. Chem. 7:1996;165-179.
5. Welt S.et al. Phase I/II study of iodine-125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J. Clin. Oncol. 14:1996;1787-1797.
6. Geissler F.et al. Intracellular catabolism of radiolabeled anti-μ antibodies by malignant B-cells. Cancer Res. 52:1992;2907-2915.
7. Govindan S.V.et al. Labeling of monoclonal antibodies with diethylenetriaminepentaacetic acid-appended radioiodinated peptides containing D-amino acids. Bioconj. Chem. 10:1999;231-240.
8. Stein R.et al. Therapy of a human lung cancer xenograft using MAb RS7 labeled with residualizing iodine. Cancer Biother. Radiopharm. 15:2000;. (abstract), (in press).
9. Gansow O.A., Wu C. Advanced methods for radiolabeling monoclonal antibodies with therapeutic radionuclides. Goldenberg D.M. Cancer Therapy with Radiolabeled Antibodies. 1995;63-76 CRC Press, Boca Raton, FL, USA.
10. Lewis M.R.et al. A facile, water-soluble method for the modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled conjugates. Bioconj. Chem. 5:1994;565-576.
11. Griffiths G.L.et al. Quantitative 5-minute radiolabeling of DOTA-HMAB conjugates with Y-90 for cancer radioimmunotherapy. J. Nucl. Med. 40:1999;150P. (abstract number 603).
12. Kukis D.L.et al. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. J. Nucl. Med. 39:1998;2105-2110.
13. Li M., Meares C.F. Synthesis, metal-chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. Bioconj. Chem. 4:1993;275-283.
14. Arano Y.et al. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels. Cancer Res. 59:1999;128-134.
15. Behr T.M.et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates. Cancer (Suppl.). 80:1997;2591-2610.
16. -/γ therapeutic radiolabel. J. Nucl. Med. 40:1999;121P. (abstract number 489).
17. Griffiths G.L. Antibody radiolabeling with isotopes of rhenium. Goldenberg D.M. Cancer Therapy with Radiolabeled Antibodies. 1995;77-86 CRC Press, Boca Raton, FL, USA.
18. McDewitt M.R.et al. Radioimmunotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med. 25:1998;1341-1351.
19. Zalutsky M.R., Bigner D.D. Radioimmunotherapy with alpha particle-emitting radioimmunoconjugates. Acta Oncol. 35:1996;373-379.
20. Nikula T.K.et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J. Nucl. Med. 40:1999;166-176.
21. 2-. Radiochim. Acta. 60:1993;1-10.
22. Zalutsky M.R.et al. Radioimmunotherapy of neoplastic meningitis in rats using an α-particle-emitting immunoconjugate. Cancer Res. 54:1994;4719-4725.
23. O'Donoghue J.A.et al. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J. Nucl. Med. 36:1995;1902-1909.
24. Goodwin D.A. Strategies for antibody targeting. Antibody Immunoconjug. Radiopharm. 4:1991;427-434.
25. Stoldt H.S.et al. Pretargeting strategies for radio-immunoguided tumour localisation and therapy. Eur. J. Cancer. 33:1997;186-192.
26. Sharkey R.M.et al. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Bioconj. Chem. 8:1997;595-604.
27. Hnatowich D.J. The in vivo uses of streptavidin and biotin: a short progress report. Nucl. Med. Commun. 15:1994;575-577.
28. Paganelli G.et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur. J. Nucl. Med. 26:1999;348-357.
29. 90Y radioimmunotherapy in a mouse xenograft model. J. Immunother. 16:1994;158. (abstract number 44).
30. Su F-M.et al. Pretargeted radioimmunotherapy in tumored mice using an in vivo Pb-212/Bi-212 generator. J. Nucl. Med. 39:1998;91P. (abstract number 354).
31. 90Y radioimmunotherapy. Proc. Am. Soc. Clin. Oncol. 14:1995;423. (abstract number 1348).
32. R) for treatment of non-Hodgkin's lymphoma (NHL): preliminary results. J. Nucl. Med. 40:1999;19P. (abstract number 75).
33. Barbet J.et al. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother. Radiopharm. 14:(1999);153-166.
34. Boerman O.C.et al. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. Cancer Res. 59:1999;4400-4405.
35. 90Y-lymphoma therapy. Cancer. 73(Suppl.):1994;966-973.
36. DeNardo S.J.et al. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc. Natl. Acad. Sci. U. S. A. 94:1997;4000-4004.
37. Roffler S.R.et al. Potentiation of radioimmunotherapy by inhibition of topoisomerase I. Cancer Res. 54:1994;1276-1285.
38. Stein R.et al. Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer. Clin. Cancer Res. 5(Suppl.):1999;3199s-3206s.
39. Behr T.M.et al. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res. 57:1997;5309-5319.
40. 131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Cancer Res. 57:1997;2181-2186.
41. Jurcic J.G., Scheinberg D.A. Radioimmunotherapy of hematological cancer: problems and progress. Clin. Cancer Res. 1:1995;1439-1446.
42. Corcoran M.C.et al. Radioimmunotherapy strategies for non-Hodgkin's lymphomas. Ann. Oncol. 8(Suppl. 1):1997;133-138.
43. Wilder R.B.et al. Radioimmunotherapy: recent results and future directions. J. Clin. Oncol. 14:1996;1383-1400.
44. Meredith R.F.et al. Recent progress in radioimmunotherapy for cancer. Oncology. 11:1997;979-987.
45. Press O.W.et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet. 346:1995;336-340.
46. Kaminski M.S.et al. Iodine-131 anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol. 14:1996;1974-1981.
47. Knox S.J.et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res. 2:1996;457-470.
48. Juweid M.et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res. (Suppl.). 55:1995;5899-5907.
49. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin. Cancer Res. (Suppl.). 5:1999;3292s-3303s.
50. 90Y-hLL2) anti-CD22 monoclonal antibody (MAb) in NHL patients who failed high-dose chemotherapy. Blood (Suppl.). 94:1999;174a. (abstract number 757).
51. 67Cu-2IT-BAT-Lym-1 and opportunities for improvement. Goldenberg D.M. Cancer Therapy with Radiolabeled Antibodies. 1995;217-227 CRC Press, Boca Raton, FL, USA.
52. Waldmann T.A. Lymphokine receptors: A target for immunotherapy of lymphomas. Ann. Oncol. 5:1994;S13-S17.
53. Vriesendorp H.et al. Recurrence of Hodgkin's disease after indium-111 and yttrium-90 labeled antiferretin administration. Cancer (Suppl.). 80:1997;2721-2727.
54. Jurcic J.G.et al. Monoclonal antibody therapy of leukemia and lymphoma. Adv. Pharmacol. 33:1995;287-314.
55. 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 85:1995;1122-1131.
56. Jurcic J.G.et al. Targeted alpha-particle therapy for myeloid leukemias: a phase-I trial of bismuth-213-HuM195 (anti-CD33). Blood (Suppl.). 90:1997;504a. (abstract number 2245).
57. Riva P.et al. Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas. Cancer (Suppl.). 80:1997;2733-2742.
58. Meredith R.F.et al. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J. Nucl. Med. 37:1996;1491-1496.
59. Behr T.M.et al. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies. J. Nucl. Med. 38:1997;409-418.
60. Dunn R.M.et al. Can occult metastases be treated by radioimmunotherapy? Cancer (Suppl.). 80:1997;2656-2659.
61. Gooden N.S.et al. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis. Oncol. Rep. 5:1998;223-226.
62. Sharkey R.M.et al. Development of cancer radioimmunotherapy and its potential as an adjuvant treatment. Goldenberg D.M. Cancer Therapy with Radiolabeled Antibodies. 1995;101-114 CRC Press, Boca Raton, FL, USA.
63. Sgouros G. Radioimmunotherapy of micrometastases: sidestepping the solid-tumor hurdle. J. Nucl. Med. 36:1995;1910-1912.